Press release


02/09/2013
ALGENEX creates the position of Head of Global Business Development
As part of its corporate strategy to supply its Top-Bac® and IBES® technology directly to the high quality protein market, ALGENEX, has created the position of Head of Global Business Development
 
As part of its corporate strategy to supply its Top-Bac® and IBES® technology directly to the high quality protein market, ALGENEX, has created the position of Head of Global Business Development and is happy to announce to have assigned Roberto Clemente PhD MBA for this new position.
ALGENEX has generated during the last 5 years a strong package of intellectual property and several commercial leads with its technology. The second phase of ALGENEX corporate strategy is now to bring in 2013 its Top-Bac® and IBES® technology as licenses to the EU and US market.
Roberto Clemente has a proven track record in developing strategic businesses for and with biotech companies. His confidence and experience is probably best summarized after he first got to know ALGENEX: “Considering the baculovirus bottlenecks in sectors such as vaccines manufacturing, structural biology, diagnostic protein supply or HTS, and the capabilities ALGENEX has acquired with its technological platforms, ALGENEX is positioning itself as a fundamental alternative to provide sustainable solutions to the pharma and biotech market”.

About Algenex
Algenex is a Spanish start-up company involved in developing new platforms, more versatile and powerful, to produce high added value molecules to both human and animal health in a cost-effective manner. Algenex has developed two disruptive platforms within baculovirus expression system (BEVS) to achieve these goals. Top-Bac® is a proprietary expression cassette that improves the quality of protein produced and in most of the cases quadruplicate the production over conventional BEVS. The other platform of Algenex is IBES®, which is based on the use of insect larvae as disposable, living bioreactors. The combination of both platforms leads to unprecedented yields of one of the most powerful BEVS-based technologies.
 
 
Related links:
 
 
Permalink  
 
Developed by Web4Bio